A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

OBJECTIVE: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1, capecitabine plus lapatinib, and trastuzumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaby, Vakaramoko, Alqhtani, Hussain, van Boemmel-Wegmann, Sascha, Wang, Ching-Yu, Ali, Askal Ayalew, Balkrishnan, Rajesh, Ko, Yu, Palacio, Sofia, de Lima Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375554/
https://www.ncbi.nlm.nih.gov/pubmed/31805500
http://dx.doi.org/10.1016/j.breast.2019.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375554/
https://www.ncbi.nlm.nih.gov/pubmed/31805500
http://dx.doi.org/10.1016/j.breast.2019.11.012

Ejemplares similares